-
Mashup Score: 0Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data - 4 year(s) ago
To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials. This pooled analysis of 16 randomized, double-blind/open-label trials, with ≥ 1 abatacept (intravenous or subcutaneous) arm, and with/without placebo control covered cumulative (controlled short-term and open-label long-term) abatacept exposure periods. OIs…
Source: Arthritis Research & TherapyCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Arthritis Research & Therapy - 4 year(s) ago
One of the world’s leading journals in the field of rheumatology, Arthritis Research & Therapy covers a broad range of autoimmune rheumatic and …
Source: Arthritis Research & TherapyCategories: Latest Headlines, RheumatologyTweet-
📢Deadline for submissions to our Digital Rheumatology collection has been extended to 31st March 2021. Full details 👉 https://t.co/hrFi7bt0b9
-
-
Mashup Score: 0
Scarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLE patients. SLE patients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring…
Source: Arthritis Research & TherapyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A study published in @ArthritisRes reports the prevalence of scarring alopecia during the disease course of systemic lupus erythematosus (SLE) and evaluates the risk factors for scarring alopecia in Chinese SLE patients. https://t.co/jTIW0M9PHA
-
-
Mashup Score: 1The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus - 4 year(s) ago
Type I interferons (IFNs) play an important role in the pathophysiology of systemic lupus erythematosus (SLE). While cross-sectional data suggest an association between IFN-induced gene expression and SLE disease activity, interest in this as a biomarker of flare has been tempered by a lack of fluctuation with disease activity in the majority of patients. This led us to question whether…
Source: Arthritis Research & TherapyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Type I interferon (IFN1) produced by plasmacytoid dendritic cells are prime drivers of adaptive immunity. Study of 137 SLE pts shows that baseline IFN1 scores correl w/ Dz activity, # flares, prednisone doses, immunosuppressive use over 5 yrs https://t.co/OGb4NfrcIU
-
-
Mashup Score: 0
Scarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLE patients. SLE patients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring…
Source: Arthritis Research & TherapyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Chinese SLE CSTAR study of 4792 SLE patients, of whom 374 (7.8%) had scarring alopecia. Risk factors for scarring alopecia included mucocutaneous lesions (OR 2.1) high SLICC/ACR-DI (OR 1.4), & positive Sm (OR 1.4), but less seen w/ renal CV involvement https://t.co/Y466WK3shS
-
-
Mashup Score: 0Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event - 4 year(s) ago
Giant cell arteritis (GCA) is frequently associated with aortic involvement that is likely to cause life-threatening structural complications (aneurysm, dissection). Few studies have investigated the occurrence of these complications, and no predictive factor has been identified so far. The aim of this study was to investigate factors associated with the risk of aortic complications in a cohort…
Source: Arthritis Research & TherapyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Retrospective study of 171 GCA patients found that 32% had aoritis (by Sxs or AI murmur); hese pts were 6 fold more likely to have subsequent Aortic complications (aortic aneurysms or dissection) https://t.co/zRVzmnU7JH
-
-
Mashup Score: 1
Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis. The study was conducted in the arthritis outpatient clinic at two large academic…
Source: Arthritis Research & TherapyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Study of 2050 Northern Italian arthritis clinic pts; where 1.1-1.4% of population developed COVID-19. Steroid use was independently associated with increased COVID risk (adj OR 1.23 to 3.20). But Rx w/ ts/bDMARDs had reduced risk (adj OR 0.46). https://t.co/cLXdpzda9t
-
-
Mashup Score: 0Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis - 4 year(s) ago
Biological therapies have improved the clinical course and quality of life of rheumatoid arthritis (RA) patients. Despite the availability and effectiveness of these treatments, some patients experience multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs), constituting a particular challenge to clinicians. This study aims to determine the percentage of rheumatoid…
Source: Arthritis Research & TherapyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A study in Arthritis Research & Therapy suggests younger patients with erosive diseases and absence of clinical response to biologic disease-modifying antirheumatic drugs should be monitored more closely and may benefit from personalized treatments. https://t.co/pybgaEYD8u
-
-
Mashup Score: 3Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis - 4 year(s) ago
Biological therapies have improved the clinical course and quality of life of rheumatoid arthritis (RA) patients. Despite the availability and effectiveness of these treatments, some patients experience multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs), constituting a particular challenge to clinicians. This study aims to determine the percentage of rheumatoid…
Source: Arthritis Research & TherapyCategories: Healthcare Professionals, Latest HeadlinesTweet-
1st refractory to DMARD can be bad omen. RA Study showed 41/402 (10%) were multi-DMARD refractory (MR) and 18% achieved remission/LDAS. DMARD MR predicted by erosions, younger age, high baseline DAS28, delta-DAS < 1.2 1st 6 mos (OR 11.12) https://t.co/KxdK97uuSI
-
-
Mashup Score: 0
Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately to severely active RA in adults in over 50 countries including European countries, the USA, and Japan. This substudy evaluated pneumococcal conjugate and tetanus toxoid…
Source: Arthritis Research & TherapyCategories: Latest Headlines, RheumatologyTweet-
Thinking about withholding drugs and the COVID-19 vaccine. Here is some baricitinib vaccination data. Conclusion: ~2/3 of patients on long-term baricitinib achieved satisfactory humoral and functional responses to pneumococcal conjugate vaccination https://t.co/ugBxy7JUt7
-
Pooled analysis of 16 RCTs in 7044 abatacept treated pts (21,274 PYs exposure) found very low risk of opportunistic infections ranging from OIs 0.17 to 0.21 on ABA and 0.56 on placebo - only 13 TB cases; IR for H zoster was low 1.53/100PY https://t.co/kOWYxEmQLd